Characterizing mammography reports for health analytics

Autor: Carlos C. Rojas, Barbara G. Beckerman, Robert M. Patton

Publikováno v: IHI

As massive collections of digital health data are becoming available, the opportunities for large-scale automated analysis increase. In particular, the widespread collection of detailed health information is expected to help realize a vision of evide

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3eee91436d15020cc58f3f9445feb9ae
https://doi.org/10.1145/1882992.1883022

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Autor: Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Bex A; Netherlands Cancer Institute, Amsterdam, the Netherlands.; University College London, London, United Kingdom., Russo P; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY., Tomita Y; Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan., Cutuli HJ; Hospital Sirio Libanés, Buenos Aires, Argentina., Rojas C; Bradford Hill, Santiago, Chile., Gross-Goupil M; Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Schinzari G; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Barthélémy P; Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Ruiz Garcia A; Hospital 1ro de Octubre, Mexico City, Mexico., Sosman J; Northwestern University Medical Center, Chicago, IL., Grimm MO; Jena University Hospital, Jena, Germany., Goh JC; ICON Research, South Brisbane, QLD, Australia., Suarez C; Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Kollmannsberger CK; BC Cancer, Vancouver, BC, Canada., Nair SG; Lehigh Valley Health Network, Allentown, PA., Shuch BM; University of California Los Angeles, Los Angeles, CA., Huang J; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China., Simsek B; Bristol Myers Squibb, Princeton, NJ., Spiridigliozzi J; Bristol Myers Squibb, Princeton, NJ., Lee CW; Bristol Myers Squibb, Princeton, NJ., van Kooten Losio M; Bristol Myers Squibb, Princeton, NJ., Grünwald V; University Hospital Essen, Essen, Germany.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 20, pp. JCO2400773. Date of Electronic Publication: 2024 Sep 20.

Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina.

Autor: Espinola N; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina., Rodríguez Cairoli F; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina., Rojas-Roque C; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.; Centre for Health Economics (CHE), Alcuin 'A' Block, University of York, York, UK., Luna PC; Dermatology Department, Hospital Alemán, Buenos Aires, Argentina., Kanevsky D; Market Access Department, AbbVie, Buenos Aires, Argentina., Migliazza V; Medical Department, AbbVie, Buenos Aires, Argentina., Pichon-Riviere A; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.; Center for Research in Epidemiology and Public Health, National Scientific and Technical Research Council, Buenos Aires, Argentina.

Publikováno v: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2024 Aug 30, pp. 1-11. Date of Electronic Publication: 2024 Aug 30.

Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.

Autor: Oh DY; Division of Medical Oncology, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.; Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea., Ikeda M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Lee CK; Division of Medical Oncology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Rojas C; Department Medical Oncology, Bradford Hill Centro de Investigación Clínica, Santiago, Chile., Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Kim JW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Furuse J; Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan., Park JO; Department of Medicine, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Borad M; Department of Hematology-Oncology, Mayo Clinic, Phoenix, Arizona, USA., de Braud F; Department Medical Oncology, University of Milan, Fondazione IRCCS Istituto Nazionale del Tumori, Milan, Italy., Bridgewater J; Department of Oncology, University College London Cancer Institute, London, UK., Lee SS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Moehler M; Department of Gastrointestinal Oncology, Mainz University Hospital, Mainz, Germany., Audhuy F; Global Medical Affairs Oncology, Merck Serono S.A.S., Lyon, France, an affiliate of Merck KGaA, Darmstadt, Germany., Osada M; Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany., Sato M; Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany., Yoo C; Asan Medical Center, Department of Oncology, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Publikováno v: Hepatology (Baltimore, Md.) [Hepatology] 2024 Jun 14. Date of Electronic Publication: 2024 Jun 14.

First Molecular Detection and Epidemiological Analysis of Equine Influenza Virus in Two Regions of Colombia, 2020-2023.

Autor: Gonzalez-Obando J; Grupo de Investigación en Ciencias Animales-GRICA, Facultad de Medicina Veterinaria y Zootecnia, Universidad Cooperativa de Colombia, Bucaramanga 680002, Colombia.; Grupo de Epidemiología, Universidad de Antioquia, Medellín 050010, Colombia., Zuluaga-Cabrera A; Grupo de Investigación GISCA, Facultad de Medicina Veterinaria y Zootecnia, Fundación Universitaria Vision de las Américas, Medellín 050031, Colombia., Moreno I; GHI One Health Colombia, Universidad Nacional de Colombia, Medellín 050036, Colombia., Úsuga J; GHI One Health Colombia, Universidad Nacional de Colombia, Medellín 050036, Colombia., Ciuderis K; GHI One Health Colombia, Universidad Nacional de Colombia, Medellín 050036, Colombia., Forero JE; Grupo de Investigación en Microbiología Ambiental, Escuela de Microbiología, Universidad de Antioquia, Medellín 050010, Colombia., Diaz A; Pig Improvement Company Hendersonville, Hendersonville, TN 37075, USA., Rojas-Arbeláez C; Grupo de Epidemiología, Universidad de Antioquia, Medellín 050010, Colombia., Hernández-Ortiz JP; GHI One Health Colombia, Universidad Nacional de Colombia, Medellín 050036, Colombia., Ruiz-Saenz J; Grupo de Investigación en Ciencias Animales-GRICA, Facultad de Medicina Veterinaria y Zootecnia, Universidad Cooperativa de Colombia, Bucaramanga 680002, Colombia.

Publikováno v: Viruses [Viruses] 2024 May 24; Vol. 16 (6). Date of Electronic Publication: 2024 May 24.